Pharmaceutical Executive: December 2023

How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.

Lisa Conte, founder, president, and CEO of Jaguar Health, discusses how a climb up Mount Kilimanjaro would vault her to her true career calling—and spark a decades-long quest to accelerate breakthroughs in plant-based pharmaceuticals and supportive care.

While hurdles remain, home healthcare could deliver better patient-centered cancer care—providing improved outcomes, enhanced quality of life, and reduced strain on resources.

Experts gauge whether the needle is finally moving on the effective structuring of outcomes centered payment agreements—from operational, technology, and acceptance standpoints.

Continuous learning a vital skill for aspiring and established leaders alike.

There’s reason to believe that a positive pivot may be in the offing.

Unprecedented policy and access issues threaten R&D momentum.

Five emerging themes likely to impact pharma in the new year.

Another year in the books.

Click the title above for a link to open the Pharmaceutical Executive December 2023 issue in an interactive PDF format.